Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension

Abstract

Get full access to this article

View all access options for this article.

References

Orenitram [package insert]. Research Triangle Park, NC: United Therapeutics; 2017.

Kaufmann

Hurst

Astruc

Dingemanse

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol. 2017;73:151-156. doi:10.1007/s00228-016-2164-4

Uptravi [package insert]. South San Francisco, CA: Actelion Pharmaceuticals; 2018.

Sitbon

Channick

Chin

et al ; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-2533. doi:10.1056/NEJMoa1503184

Coghlan

Channick

Chin

et al . Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018;18:37-47. doi:10.1007/s40256-017-0262-z